Výsledky vyhledávání

Cytoprotection in Chemo – and Radiotherapy with Amifostine (Ethyol): A New Strategy in Oncology

Autor: J. Schuth, R.A. Kudielka, A. Rieth

Publikováno v: Oncology Research and Treatment. 19:315-320

Amifostine (WR-2721, Ethyol), a phosphorylated aminothiol, was originally developed as a radioprotective agent. Since numerous preclinical studies showed that, following dephos-phorylation to the active thiol WR-1065, amifostine selectively protected

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a88c33a2eb35af026e3037fa5065b334
https://doi.org/10.1159/000218821

Zobrazit plný text záznamu

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

Autor: E. Marg, Andrew Brenner, Ulrich Bogdahn, Peter Hau, Dorothee Koch, B. Bauer, J. Schuth, P. Rieckmann, Horst J. Koch, Michael Rauch, Tanja Jauch, Thomas Hundsberger, R. Rudolph

Publikováno v: Neurology. 68(9)

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2e4848d8ad60cd768b0a29b802382fa
https://pubmed.ncbi.nlm.nih.gov/17325277

Zobrazit plný text záznamu

[Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma]

Autor: J, Büntzel, M, Glatzel, J, Schuth, R, Weinaug, K, Küttner, D, Fröhlich

Publikováno v: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. 175

The radiotherapeutic possibilities are limited for patients with a recurrent or second head and neck cancer if the patient was already irradiated in the first therapy. In the presented study we investigated the changes of this situation due to the us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6b53dcab07f2ccc2bb44f3895f6339e6
https://pubmed.ncbi.nlm.nih.gov/10584140

Zobrazit plný text záznamu

Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial

Autor: Ulrich Herrlinger, M. Weller, Michael Bamberg, Dorothee Wiewrodt, A. von Deimling, Markus Weiler, J. Schuth, Christian Hartmann, W Wick

Publikováno v: Journal of Clinical Oncology. 26:2044-2044

2044 Background: To evaluate toxicity and efficacy of an intensified schedule of temozolomide plus indomethacin in addition to standard radiotherapy plus concomitant temozolomide in patients (pts) with newly diagnosed glioblastoma. Methods: This tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2071bc861f14aeb823aacbd9a52ce67
https://doi.org/10.1200/jco.2008.26.15_suppl.2044

Zobrazit plný text záznamu

One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma

Autor: M. Weller, G. Reifenberger, J. Schuth, Antje Wick, Michael Platten, W. Wick

Publikováno v: Journal of Clinical Oncology. 25:2032-2032

2032 Background: Evaluation of toxicity and efficacy of a one week on/one week off temozolomide regimen in patients with recurrent gliomas. Methods: Ninety adult patients (median Karnofsky performance score 90; median age 51 years) with recurrent gli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::67766b76a2070a53dddf36fb8fca00d4
https://doi.org/10.1200/jco.2007.25.18_suppl.2032

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání